These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1371563)

  • 1. Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer.
    Kennedy TJ; Sonneland AM; Marlett MM; Troup RH
    J Urol; 1992 Mar; 147(3 Pt 2):891-3. PubMed ID: 1371563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
    Arai Y; Yoshiki T; Yoshida O
    J Urol; 1990 Dec; 144(6):1415-9. PubMed ID: 1700155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
    Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
    J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.
    Trachtenberg J
    J Urol; 1983 Jun; 129(6):1149-52. PubMed ID: 6406688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
    Seidman AD; Scher HI; Petrylak D; Dershaw DD; Curley T
    J Urol; 1992 Mar; 147(3 Pt 2):931-4. PubMed ID: 1371564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
    Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
    BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
    Ouzaid I; Rouprêt M
    Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
    Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
    Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging.
    McSherry SA; Levy F; Schiebler ML; Keefe B; Dent GA; Mohler JL
    J Urol; 1991 Jul; 146(1):85-9. PubMed ID: 1711590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
    Mitsumori M; Sasaki Y; Mizowaki T; Takayama K; Nagata Y; Hiraoka M; Negoro Y; Sasai K; Kinoshita H; Kamoto T; Ogawa O
    Int J Clin Oncol; 2006 Oct; 11(5):396-402. PubMed ID: 17058138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels.
    Yuan JJ; Coplen DE; Petros JA; Figenshau RS; Ratliff TL; Smith DS; Catalona WJ
    J Urol; 1992 Mar; 147(3 Pt 2):810-4. PubMed ID: 1371553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
    Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
    Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
    Carter HB; Partin AW; Epstein JI; Chan DW; Walsh PC
    J Urol; 1990 Nov; 144(5):1167-70; discussion 1170-1. PubMed ID: 1700143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
    Lawrentschuk N; Fernandes K; Bell D; Barkin J; Fleshner N
    J Urol; 2011 Mar; 185(3):848-54. PubMed ID: 21239017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.